QuidelOrtho [NASDAQ: QDEL]
Breaking Barriers in Diagnostics: Faster, Smarter Testing

QuidelOrtho, a leader in diagnostic innovation, combines expertise in molecular testing, immunoassays, and clinical diagnostics to develop cutting-edge platforms like Savanna and Sofia. Savanna is a versatile molecular diagnostics platform that delivers rapid, multiplexed testing at the point of care, while Sofia is an advanced immunoassay system leveraging fluorescence technology for fast and reliable outcomes in infectious diseases, cardiac markers and women’s health. By providing rapid and accurate diagnostics, the company empowers healthcare providers to make timely, informed decisions that improve patient outcomes.

QuidelOrtho was formed through the merger of Ortho Clinical Diagnostics and Quidel Corporation, combining Ortho’s legacy of pioneering blood safety advancements with Quidel’s expertise in rapid diagnostics. This strengthens the company’s ability to innovate, creating a comprehensive diagnostic ecosystem that spans high volume laboratory systems and nimble point-of-care tools.

“Our commitment to excellence, inclusivity, and customer service drives transformative diagnostic innovations, improving healthcare accessibility and ultimately contributing to global health,” says Brian J. Blaser, president and CEO.

Building on this commitment, QuidelOrtho is focusing on leadership and transformational strategies to drive innovation forward. By leveraging advanced technology and global expertise, the company is enhancing the performance and reach of its diagnostic solutions, ensuring that healthcare providers worldwide have the tools they need to deliver timely, life changing care. This dedication to innovation and rapid response was exemplified during the 20 APAC JULY - AUGUST 2025 Brian J. Blaser, President and CEO COVID-19 pandemic, a defining moment that tested the resilience and adaptability of healthcare systems worldwide.

During the COVID-19 pandemic, within weeks, the company scaled up production of its Sofia SARS Antigen FIA test, a rapid fluorescence immunoassay designed for the qualitative detection of SARS-CoV-2 antigens, distributing millions of kits across 50 countries. This rapid response alleviated hospital burdens, improved outbreak tracking and highlighted the vital role of diagnostics in worldwide health security. While the pandemic emphasized the need for rapid testing, QuidelOrtho’s technologies extend beyond crisis response. The company has transformed women’s health, enabling early detection of conditions like preeclampsia and gestational diabetes. In emergency departments, cardiac biomarker tests speed up heart attack diagnoses, while laboratory systems support the long term management of chronic conditions like diabetes with unwavering accuracy.

Understanding that the greatest breakthroughs happen together, QuidelOrtho collaborates with hospitals, academic institutions, and global organizations like the World Health Organization to amplify its impact, turning innovation into real world change. These partnerships drive solutions for emerging health threats, such as multiplex testing for identifying multiple pathogens from a single sample to advancing infection management. Also, engineers are creating portable, user friendly devices for underserved regions, requiring minimal power and training, improving access to essential diagnostics in resource-limited settings. Sustainability is woven into every development, from water-efficient manufacturing processes to recyclable test components, proving that modern science and environmental stewardship can coexist.

This commitment to responsible innovation extends beyond production practices to the very communities QuidelOrtho serves.

With a strong foundation in diagnostic excellence, QuidelOrtho is now investing in next-generation technologies such as liquid biopsy—a breakthrough in early cancer detection through non-invasive blood analysis. In addition, its AI-driven predictive analytics are exploring ways to forecast disease risk based on genetic and lifestyle data. These advancements signal a future where diagnostics shift from reactive treatment to proactive prevention, enabling early intervention for conditions like Alzheimer’s and diabetes. Achieving this vision requires not just cutting-edge science but also practical tools that deliver accurate results quickly and reliably in diverse healthcare settings.

QuidelOrtho’s story goes beyond test results and lab reports—it is a testament to human resilience, where science bridges gaps, and equitable access to diagnostics transforms lives. In every test performed and every life touched, the company reaffirms its commitment to a healthier, more connected world—one where knowledge empowers action and innovation fuels hope.